摘要
观察藻酸双酯钠（ＰＳＳ）对肾病综合症和实验性原位性肾炎的影响。肾病综合症（ＮＳ）Ⅰ型患者 ３５人，治疗组１８例，对照组１７例，治疗组除加用 ＰＳＳ外，其它治疗同对照组；阳离子化牛血清蛋白（Ｃ—ＢＳＡ）建立原位性肾炎模型，用ＰＳＳ进行治疗ＮＳ患者用ＰＳＳ治疗能明显减轻尿蛋白，降低血胆固醇和甘油三酯，减少深静脉血栓形成的机会；ＰＳＳ能干扰原位性肾炎模型的建立，干扰组没有出现明显肾小球病变，大鼠无明显蛋白尿，而模型组则出现明显肾小球病变，大量尿蛋白和肾功能减退。ＰＳＳ能干扰实验性原位性肾炎形成；临床上ＰＳＳ治疗ＮＳ 患者能减轻尿蛋白，其机理可能是ＰＳＳ干扰免疫复合物（ＩＣ）在肾小球沉积。
objective: To investigate the effects of polysaccride sodium (PSS)in treating pa tients with nephrotic syndrome (NS)and experimental in situ nephritis. Methords 35 patients with NS were freedom divided into two groups. All patients were treated with the same methords (including prednison persantin ets), 18 patients were added PSS 0. 1 tid. In situ nephritis was established by administrating cationic bovine serum albumin (C-BSA)and in terfered by PSS. Ressults: Urine protein excretion and serum CH, TG, HDI--CH were sig nificantly decreased in the group treated with PSS. The cats treated with PSS showed no sig nificant lesion in the gromeruli and no urine protein excretion compared with C-BSA group. Conclusion: PSS plays a role in treating NS patients and interferes in situ nephritis. It sug gests that PSS could interfere immune complex(IC) deposition in glomeruli.
出处
《中国海洋药物》
CAS
CSCD
1999年第4期48-50,共3页
Chinese Journal of Marine Drugs
关键词
藻酸双酯钠
肾病综合症
药物疗法
Polysaccride sodium, in situ nephritis, nephrotic sydrome.
